TerrAscend (TSNDF) Non-Current Assets (2021 - 2026)
TerrAscend's (TSNDF) quarterly Non-Current Assets came in at $446.7 million in Q1 2026, down 10.59% year-on-year from $499.5 million in Q1 2025, and little changed on a QoQ basis from $447.3 million in Q4 2025.
TerrAscend (TSNDF) Non-Current Assets (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Non-Current Assets data on file, last reported at $446.7 million in Q1 2026.
- On a quarterly basis, Non-Current Assets fell 10.59% year-over-year to $446.7 million in Q1 2026; TTM through Mar 2026 was $446.7 million, a 10.59% decrease from a year earlier, with the FY2025 full-year figure at $447.3 million, up 3.93% from the prior year.
- Non-Current Assets for Q1 2026 stood at $446.7 million, roughly flat from $447.3 million in the prior quarter.
- Over the last five years, Non-Current Assets for TSNDF reached as high as $871.3 million in Q2 2022 and fell as low as $430.3 million in Q4 2024.
- Historically, Non-Current Assets has averaged $568.8 million across 5 years, with a median of $557.9 million in 2024.
- Across the five-year window, Non-Current Assets soared 41.56% in 2022 and slumped 30.79% in 2023, its largest moves.
- Year by year, Non-Current Assets stood at $579.6 million in 2022, then slipped by 2.75% to $563.6 million in 2023, then decreased by 23.65% to $430.3 million in 2024, then grew by 3.93% to $447.3 million in 2025, then retreated by 0.14% to $446.7 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $446.7 million in Q1 2026, $447.3 million in Q4 2025, and $435.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn | 446.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 446.66 Mn |
| Dec 31, 2025 | 447.27 Mn |
| Sep 30, 2025 | 435.90 Mn |
| Jun 30, 2025 | 438.92 Mn |
| Mar 31, 2025 | 499.54 Mn |
| Dec 31, 2024 | 430.34 Mn |
| Sep 30, 2024 | 551.22 Mn |
| Jun 30, 2024 | 555.44 Mn |
| Mar 31, 2024 | 557.88 Mn |
| Dec 31, 2023 | 563.63 Mn |
| Sep 30, 2023 | 627.45 Mn |
| Jun 30, 2023 | 615.12 Mn |
| Mar 31, 2023 | 587.79 Mn |
| Dec 31, 2022 | 579.59 Mn |
| Sep 30, 2022 | 612.09 Mn |
| Jun 30, 2022 | 871.30 Mn |
| Mar 31, 2022 | 849.27 Mn |
| Dec 31, 2021 | 409.45 Mn |